Sharing our perspective

Sharing perspectives leads to greater understanding and fuels innovation. The ​Optum Insights ​blog is where we share our perspective and challenge preconceptions to clear a new path forward.


  • Louisiana latest to adopt initial limits for Opioid Analgesics

    by
    • Optum Workers' Comp
    | Jun 20, 2017
    Tag Icon
    Opioids
    Louisiana Governor John Bel Edwards recently signed into law HB 192, sponsored by Representative Helena Moreno – D (Orleans Parish). HB 192 has several components that are similar to the opioid limit laws that have passed in other states. The bill amends the Louisiana Public Health and Safety law R.S. 40:978 by adding section (G) limiting the initial prescription for an opioid analgesic for treating acute pain to a seven-day supply. This section does give some flexibility to the treating physician to prescribe more than a seven-day supply if, “in the professional medical judgment of a medical practitioner, more than a seven-day supply of an opioid is required to treat the adult or minor patient’s acute medical condition...” This section would also require the practitioner to document, in the patient’s medical record, the condition triggering the need for an opioid analgesic beyond the seven-day prescribing limit.


  • Medication recall for one lot of Eliquis® (apixaban)

    by
    • Optum Workers' Comp
    | Jun 15, 2017
    Tag Icon
    Medication Recall
    Bristol-Myers Squibb Company announced a consumer-level recall on one lot of Eliquis® (apixaban) 5 mg tablets were mislabeled due to a complaint from a customer who found Eliquis 2.5 mg tablets in their bottle that should have contained 5 mg tablets.


  • Generic Roxicodone® tablets approved by FDA

    by
    • Optum Workers' Comp
    | Jun 14, 2017
    Tag Icon
    Opioids, FDA
    The U.S. Food and Drug Administration (FDA) has approved a generic version of Mallinckrodt Inc.’s Roxicodone® tablets. Oxycodone hydrochloride is an immediate-release opioid analgesic indicated to manage pain severe enough to require an opioid analgesic and for which alternative treatment options are inadequate.


  • FDA requests removal of Opana® ER; Endo Pharmaceuticals evaluating options

    by
    • Optum Workers' Comp
    | Jun 09, 2017
    Tag Icon
    Opioids, Medication Recall, FDA
    The U.S. Food and Drug Administration (FDA) came out with a historic request of Endo Pharmaceuticals late yesterday, Thursday, afternoon to voluntarily remove its reformulated Opana ER (oxymorphone hydrochloride extended-release tablets) from the market. The request follows an FDA advisory committee review of all available post-marketing data determining the routes of abuse of Opana ER have dramatically changed; shifting from nasal to injection. Such abuse has been associated with an increase in cases of HIV and hepatitis C, as well as a serious blood disorder, thrombotic microangiopathy, in certain populations.






Subscribe

Stay informed by signing up to receive newsletters, alerts, insights and videos.
You can customize your content preferences after you subscribe.